Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00892762 | Travoprost APS Versus Xalatan® in Patient Reported Outcomes and Ocular Surface Health | PHASE3 | COMPLETED | 434 | — | — | Jun 1, 2009 | May 1, 2011 | Jul 15, 2014 | - | — |
| Arm | Type | Description |
|---|---|---|
| Travoprost APS | EXPERIMENTAL | Travoprost APS 40 micrograms/ml eye drop solution, 1 drop in the study eye(s), once daily each evening, for 90 days |
| XALATAN | ACTIVE_COMPARATOR | Latanoprost 50 micrograms/ml eye drop solution, 1 drop in the study eye(s), once daily each evening, for 90 days |
| Name | Type | Description |
|---|---|---|
| Travoprost APS 40 micrograms/ml eye drop solution | DRUG | non-BAK (benzalkonium chloride) medication |
| Latanoprost 50 micrograms/ml eye drop solution | DRUG | BAK-preserved medication |
Inclusion Criteria: * Must have a clinical diagnosis of open-angle glaucoma (with or without pseudoexfoliation or pigment dispersion component), or ocular hypertension in at least 1 eye. * Must be willing and able to discontinue use of any topical ocular medication other than the study medication f...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 3 | PHASE4 | Travoprost Intraocular |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE4 | Test - Bimatoprost 0.01%, Reference - LUMIGAN |
| AbbVie, Inc. | ABBV | 1 | PHASE4 | Bimatoprost |
| United Therapeutics Corporation | UTHR | 1 | PHASE4 | Nicotinomide |
| Alcon AG | ALC | 3 | PHASE4 | Undisclosed |